Quarterly report · Q3
4361.TEDINET S100RZJW
Period2022-12-01 → 2023-08-31
Filed2023-10-11
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥6.2bn | 2022-12-01 → 2023-08-31 | Cons. | Net sales |
| Revenue | ¥8.4bn | 2021-12-01 → 2022-11-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥6.1bn | 2021-12-01 → 2022-08-31 | Cons. | Net sales |
| Operating income | ¥216m | 2022-12-01 → 2023-08-31 | Cons. | Operating income |
| Operating income | ¥331m | 2021-12-01 → 2022-08-31 | Cons. | Operating income |
| Ordinary income | ¥209m | 2022-12-01 → 2023-08-31 | Cons. | Ordinary income |
| Ordinary income | ¥303m | 2021-12-01 → 2022-11-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥345m | 2021-12-01 → 2022-08-31 | Cons. | Ordinary income |
| Profit before tax | ¥208m | 2022-12-01 → 2023-08-31 | Cons. | Income before income taxes |
| Profit before tax | ¥343m | 2021-12-01 → 2022-08-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥158m | 2022-12-01 → 2023-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥219m | 2021-12-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥266m | 2021-12-01 → 2022-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥158m | 2022-12-01 → 2023-08-31 | Cons. | Profit loss |
| Net income | ¥266m | 2021-12-01 → 2022-08-31 | Cons. | Profit loss |
| Total assets | ¥8.2bn | at 2023-08-31 | Cons. | Assets |
| Total assets | ¥8.3bn | at 2022-11-30 | Cons. | Assets |
| Total assets | ¥8.3bn | at 2022-08-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.7bn | at 2023-08-31 | Cons. | Liabilities |
| Total liabilities | ¥5.9bn | at 2022-11-30 | Cons. | Liabilities |
| Net assets / equity | ¥2.5bn | at 2023-08-31 | Cons. | Net assets |
| Net assets / equity | ¥2.4bn | at 2022-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.5bn | at 2022-08-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.0bn | at 2023-08-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥911m | at 2022-11-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥129.9 | 2022-12-01 → 2023-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.73 | 2023-06-01 → 2023-08-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥179.75 | 2021-12-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥218.07 | 2021-12-01 → 2022-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥71.01 | 2022-06-01 → 2022-08-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 30.8% | at 2023-08-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.0% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.6% | at 2022-08-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q3r_E01006-000Pharmaceutical Productsreportable segment | revenue | 2022-12-01 → 2023-08-31 | ¥6.1bn |
| jpcrp040300-q3r_E01006-000Pharmaceutical Productsreportable segment | revenue external | 2022-12-01 → 2023-08-31 | ¥6.1bn |
| jpcrp040300-q3r_E01006-000Pharmaceutical Productsreportable segment | segment profit | 2022-12-01 → 2023-08-31 | ¥193m |
| jpcrp040300-q3r_E01006-000Real Estate Leasingreportable segment | revenue | 2022-12-01 → 2023-08-31 | ¥29m |
| jpcrp040300-q3r_E01006-000Real Estate Leasingreportable segment | revenue external | 2022-12-01 → 2023-08-31 | ¥29m |
| jpcrp040300-q3r_E01006-000Real Estate Leasingreportable segment | segment profit | 2022-12-01 → 2023-08-31 | ¥23m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-12-01 → 2023-08-31 | ¥6.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-12-01 → 2023-08-31 | ¥6.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-12-01 → 2023-08-31 | ¥216m |
| jpcrp040300-q3r_E01006-000Pharmaceutical Productsreportable segment | revenue | 2021-12-01 → 2022-08-31 | ¥6.1bn |
| jpcrp040300-q3r_E01006-000Pharmaceutical Productsreportable segment | revenue external | 2021-12-01 → 2022-08-31 | ¥6.1bn |
| jpcrp040300-q3r_E01006-000Pharmaceutical Productsreportable segment | segment profit | 2021-12-01 → 2022-08-31 | ¥308m |
| jpcrp040300-q3r_E01006-000Real Estate Leasingreportable segment | revenue | 2021-12-01 → 2022-08-31 | ¥29m |
| jpcrp040300-q3r_E01006-000Real Estate Leasingreportable segment | revenue external | 2021-12-01 → 2022-08-31 | ¥29m |
| jpcrp040300-q3r_E01006-000Real Estate Leasingreportable segment | segment profit | 2021-12-01 → 2022-08-31 | ¥23m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-12-01 → 2022-08-31 | ¥6.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-12-01 → 2022-08-31 | ¥6.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-12-01 → 2022-08-31 | ¥331m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 340
| Item | Context | Value | Unit |
|---|---|---|---|
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Voting rights (text) | FilingDateInstant | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | Original text (Japanese)株主としての権利内容に制限のない、標準となる株式 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | Original text (Japanese)同上 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | Original text (Japanese)同上 | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)川口化学工業株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都千代田区内神田２丁目８番４号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Notes uncertainties of entitys ability to continue as going concern quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in scope of consolidation or equity method (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes accounting treatments specific to quarterly financial statements quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |